Vascular Biogenics - VBLT Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Vascular Biogenics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VBLT, but not buy additional shares or sell existing shares.
View analyst ratings for Vascular Biogenics or view top-rated stocks.

4 equities research analysts have issued twelve-month target prices for Vascular Biogenics' stock. Their VBLT stock forecasts range from $4.00 to $5.50. On average, they predict Vascular Biogenics' stock price to reach $4.88 in the next twelve months. This suggests a possible upside of 1,961.3% from the stock's current price.
View analysts' price targets for Vascular Biogenics or view top-rated stocks among Wall Street analysts.

Vascular Biogenics' stock was trading at $1.97 at the beginning of 2022. Since then, VBLT stock has decreased by 88.0% and is now trading at $0.2365.
View the best growth stocks for 2022 here.

Vascular Biogenics is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Vascular Biogenics.

Vascular Biogenics Ltd. (NASDAQ:VBLT) issued its quarterly earnings results on Tuesday, May, 17th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The biopharmaceutical company earned $0.11 million during the quarter, compared to analyst estimates of $0.20 million. Vascular Biogenics had a negative trailing twelve-month return on equity of 69.21% and a negative net margin of 4,894.40%. During the same period in the prior year, the business posted ($0.12) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Shares of VBLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VBLT stock can currently be purchased for approximately $0.24.

Vascular Biogenics (NASDAQ:VBLT) has a market capitalization of $16.40 million and generates $770,000.00 in revenue each year. The biopharmaceutical company earns $-29,920,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

Vascular Biogenics employs 41 workers across the globe.

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The official website for Vascular Biogenics is www.vblrx.com. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at ir@vblrx.com, or via fax at 972-8993-5001.